Entecavir: Difference between revisions
Jump to navigation
Jump to search
imported>David E. Volk mNo edit summary |
imported>Robert W King (fixing image alignment) |
||
Line 4: | Line 4: | ||
{{Chem infobox | {{Chem infobox | ||
|align=right | |align=right | ||
|image=[[Image:Entecavir structure.jpg| | |image=[[Image:Entecavir structure.jpg|center|thumb|150px|{{#ifexist:Template:Entecavir structure.jpg/credit|{{Entecavir structure.jpg/credit}}<br/>|}}Entecavir]] | ||
|width=150px | |width=150px | ||
|molname=entecavir | |molname=entecavir |
Revision as of 11:45, 24 March 2008
| |||||||
entecavir | |||||||
| |||||||
Uses: | Hepatitis B | ||||||
Properties: | guanine analog, polymerase inhibitor | ||||||
Hazards: | see drug interactions | ||||||
|
Entecavir, sold under the brand name Baraclude® is an oral antiviral drug used to treat hepatitis B infection. Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). In the triphosphate form, it competes with the natural DNA base deoxyguanosine triphosphate (dGTP) for incorporation into the negative and positive strand DNA synthesis.
Chemistry
Its IUPAC chemical name is 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one and it has chemical formula C12H15N5O3.
External links
- Entecavir - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Template:MedMaster
- Template:DrugBank